Pluvicto, an innovative radiopharmaceutical manufactured in Spain to treat metastatic castration-resistant prostate cancer, has received the ABC Health Award 2026 and has proven to be an effective option by significantly reducing the risk of death and progression in patients who have exhausted other treatments. #CáncerDePróstata #Pluvicto #SaludInnovadora (translated)
